Status:
TERMINATED
Effectiveness of KOS-862 in the Treatment of Lung Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having fa...
Detailed Description
To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cance...
Eligibility Criteria
Inclusion
- At least 18 years of age
- Measurable disease
- One previous treatment of a platinum based drug such as cisplatin or carboplatin
- At least 3 weeks since last surgery/radiation/chemotherapy
Exclusion
- Brain metastases
- Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
November 1 2004
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00080509
Start Date
December 1 2003
End Date
November 1 2004
Last Update
February 3 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.